

Vážené kolegyně, vážení kolegovia,  
pozývame vás na vedeckú prednášku v rámci cyklu  
**“Jesenné stretnutia v Parku”**

**Dr. Peter Čamaj**

**“Hypometylácia Sox9-Promótoru spôsobuje konštitutívnu aktiváciu hypoxiou indukovaných génov: Príčina metastázovania a angiogenézy pankreatických tumorov”**

Dňa **11. 10. 2017 o 17:00**  
v Konferenčnej miestnosti VP UK  
Ilkovičova 8, Bratislava



**Dr. Peter Čamaj je absolvent PriFUK (odbor Biochémia v r. 1995), dlhodobo pôsobiaci na viacerých nemeckých akademických inštitúciách, kde sa venoval prevažne molekulárnej onkológii.**

**Vybraná bibliografia prednášajúceho:**

1. **Camaj P.** et al. Hypoxia-Independent Gene Expression Mediated by SOX9 Promotes Aggressive Pancreatic Tumor Biology. *Mol Cancer Res.* 12(3):421-32. 2014
2. Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, Nelson PJ, Ellwart JW, Bruns CJ, **Camaj P.** Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. *Target Oncol.* 10(4):535-48, 2015
3. **Camaj P.**, Primo S, Wang Y, Heinemann V, Zhao Y, Laubender RP, Stintzing S, Giessen-Jung C, Jung A, Gamba S, Bruns CJ, Modest DP. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. *Future Oncol.* 11(13):1919-29, 2015
4. Niess H, **Camaj P.**, Mair R, Renner A, Zhao Y, Jäckel C, Nelson PJ, Jauch KW, Bruns CJ. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular "pseudoinflammation" contributing to an aggressive phenotype. *Oncotarget* 6(5):3306-18, 2015
5. Gamba S, **Camaj P.**, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. *Anticancer Drugs* 26(4):371-8, 2015
6. Zhao L, Zhao Y, Schwarz B, Mysliwietz J, Hartig R, **Camaj P.**, Bao Q, Jauch KW, Guba M, Ellwart JW, Nelson PJ, Bruns CJ. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. *Int J Oncol.* 49(1):99-110, 2016
7. Zhao Y, Altendorf-Hofmann A, Pozios I, **Camaj P.**, Däberitz T, Wang X, Niess H, Seeliger H, Popp F, Betzler C, Settmacher U, Jauch KW, Bruns C, Knösel T. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. *J Cancer Res Clin Oncol.* 143(6):1061-1068. 2017

**Tešíme sa na stretnutie,**

**za organizátorov,**

**Stano Stuchlík**

